SWOG clinical trial number
S1826

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Open
Phase
Accrual
31%
Abbreviated Title
Phase III Study of AVD plus nivolumab or BV in pts >/= 12 years in newly diagnosed, advanced cHL
Status Notes
Activation - Effective 7/19/19
Activated
07/19/2019
Participants
ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS LISTED ON TITLE PAGE

Research committees

Lymphoma

Treatment

Doxorubicin Filgrastim Vinblastine Sulfate Radiation Therapy Pegfilgrastim Nivolumab Brentuximab Vedotin Dacarbazine RT

Eligibility Criteria Expand/Collapse

See Section 5.0 of the S1826 protocol posted on www.ctsu.org

Publication Information Expand/Collapse

2020

An Intergroup Approach for Advanced Stage Classical Hodgkin Lymphoma (cHL) in Adolescents and Young Adults (AYA): SWOG S1826

S Castellino;M Leblanc;A Herrera;S Parsons;A Punnett;D Hodgson;S Rutherford;N Kahn;L Constine;K Davidson;A Prica;JW Friedberg;K Kelly INTERNATIONAL SYMPOSIUM ON CHILDHOOD, ADOLESCENT AND YOUNG ADULT HODGKIN LYMPHOMA (ISCAYAHL) (5/13-16/20, Berlin, Germany)

An Intergroup Collaboration for Advanced Stage Classical Hodgkin Lymphoma (cHL) in Adolescents and Young Adults (AYA): SWOG S1826

S Castellino;M LeBlanc;A Herrera;S Parsons;S Punnett;D Hodgson;S Rutherford;N Kahn;L Constine;K Davidson;A Prica;JW Friedberg;K Kelly J Clin Oncol 38: 2020 (suppl; abstr TPS8067); American Society of Clinical Oncology 2020 Annual Meeting, TIPS poster

Reply to LTE, Interim PET assessment of advanced Hodgkin Lymphoma: is it sufficient? [Letter to Editor]

D Stephens;H Schoder;H Li;J Friedberg Journal of Nuclear Medicine Sep 11;jnumed.120.242685. doi: 10.2967/jnumed.120.242685. Online ahead of print.

PMid: PMID32917781

SWOG S1826: A Phase III, Randomized Study of Nivolumab Plus AVD or Brentuximab Vedotin Plus AVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

A Herrera;H Li;S Castellino;S Rutherford;A Evens;K Davidson;A Punnett;L Constine;D Hodgson;S Parsons;A Prica;L Kostakoglu;M Shipp;M Leblanc;C Laubach;M Crump;B Kahl;JP Leonard;K Kelly;S Smith;JW Friedberg American Society of Hematology (December 5-8, 2020, virtual), poster presentation

An Evaluation of Activation of a National Cancer Trials Network (NCTN) trial for Hodgkin Lymphoma (HL) at Children’s Oncology Group (COG) Institutions

S Castellino;A Punnett;S Parsons;N Degroote;S Muehle;M Roth;A Herrera;JW Friedberg;N Siebel;K Kelly American Society of Hematology (December 5-8, 2020, virtual), poster presentation

Reports & Approvals

Trial Locations